ConductScience.org, home

Paper42016346

Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.

Wang W and 1 other. Int J Nanomedicine, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation. Papers, record 42016346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42016346

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.
PubMed
Journal
Int J Nanomedicine
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang WWenjie
2Wang QQinghttps://orcid.org/0009-0006-4427-7820

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Heart FailureMajor topic
NanomedicineMajor topic
Humans
Animals
Drug Delivery Systems
Regeneration
Nanoparticles

Source PubMed

Download CSV of topics

References141

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133233847Mitochondria-Targeted Drug Delivery in Cardiovascular Disease: A Long Road to Nano-Cardio Medicine.Pharmaceutics2020https://conductscience.org/library/papers/33233847PubMed
233071711Biodegradable nanofibrous temperature-responsive gelling microspheres for heart regeneration.Adv Funct Mater2020https://conductscience.org/library/papers/33071711PubMed
323889805Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology.EPMA J2013https://conductscience.org/library/papers/23889805PubMed
435456592Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment.Pharmaceutics2022https://conductscience.org/library/papers/35456592PubMed
539267789Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury.Theranostics2024https://conductscience.org/library/papers/39267789PubMed
629920798Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases.Adv Mater2018https://conductscience.org/library/papers/29920798PubMed
727679742Small mammalian animal models of heart disease.Am J Cardiovasc Dis2016https://conductscience.org/library/papers/27679742PubMed
839036340Biomedical applications of stimuli-responsive nanomaterials.MedComm (2020)2024https://conductscience.org/library/papers/39036340PubMed
931682098Lanthanide Metal-Organic Framework Nanoprobes for the In Vitro Detection of Cardiac Disease Markers.ACS Appl Mater Interfaces2019https://conductscience.org/library/papers/31682098PubMed
1019465864Patient-, provider-, and system-level barriers to heart failure care.J Cardiovasc Nurs2009https://conductscience.org/library/papers/19465864PubMed
1139218342Nanomedicine: A great boon for cardiac regenerative medicine.Eur J Pharmacol2024https://conductscience.org/library/papers/39218342PubMed
1235507131Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.Drug Deliv Transl Res2022https://conductscience.org/library/papers/35507131PubMed
1341210329Nanoparticle-based drug delivery systems targeting inflammatory immune mechanisms in acute myocardial infarction: current advances and perspectives.Front Cardiovasc Med2025https://conductscience.org/library/papers/41210329PubMed
1438089921Progress and prospect of nanotechnology for cardiac fibrosis treatment.Interdiscip Med2023https://conductscience.org/library/papers/38089921PubMed
1539220195Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.Int J Nanomedicine2024https://conductscience.org/library/papers/39220195PubMed
1620417314Inorganic nanomedicine--part 2.Nanomedicine2010https://conductscience.org/library/papers/20417314PubMed
1734622671Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice.J Am Heart Assoc2021https://conductscience.org/library/papers/34622671PubMed
1841197833The application of nanomedicines in repairing damage in myocardial infarction.J Control Release2025https://conductscience.org/library/papers/41197833PubMed
199403633Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation.Circulation1997https://conductscience.org/library/papers/9403633PubMed
2039385310Exosomes in nanomedicine: a promising cell-free therapeutic intervention in burn wounds.Stem Cell Res Ther2024https://conductscience.org/library/papers/39385310PubMed

See all 141 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42016346

GET https://conductscience.org/api/papers/v1/42016346/references?page=2